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Background. Treatment outcomes of multidrug-resistant tuberculosis (MDR TB) remain poor, particularly for fluoroquino-
lone-resistant (FQ-R) MDR TB. The aim of this study was to determine treatment outcomes and factors associated with failure of 
MDR TB treatment, focusing on FQ resistance.
Methods. Medical records were retrospectively reviewed of patients diagnosed and treated for MDR TB from January 2005 
through December 2017 at Severance Hospital, South Korea.
Results. Of a total of 129 patients with MDR TB, 90 (69.8%) cases were FQ-sensitive (FQ-S) and 39 (30.2%) were FQ-R. FQ-R 
MDR TB was associated with more severe clinical symptoms, including cavitary lesions and bilateral disease, and tended to require 
treatment with a greater number of drugs for a longer period of time than FQ-S MDR TB. Linezolid (51.3% vs 7.8%, P <  .001), 
bedaquiline (20.5% vs 8.9%, P = .083), and delamanid (10.3% vs 5.6%, P = .452) were more frequently used in FQ-R cases. Overall, 
95/124 patients (76.6%) had favorable treatment outcomes, and we did not detect a significant difference between FQ-R and FQ-S 
(FQ-S 65/87, 74.7%, vs FQ-R 30/37, 81.1%; P = .443). Old age, low body mass index, smoking, and malignancy—but not FQ resis-
tance or extensively drug-resistant (XDR) TB—were associated with poor clinical outcomes.
Conclusions. Overall, 76.6% of MDR TB patients had successful treatment outcomes. Effective drug combinations and appro-
priate use of new drugs may improve treatment outcomes of FQ-R MDR and XDR TB. Poor clinical outcomes were more related to 
the patients’ general condition rather than FQ resistance or XDR.
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Multidrug-resistant tuberculosis (MDR TB) is an important pub-
lic health problem, and adequate management of MDR TB is 
essential for effective TB control. The World Health Organization 
(WHO) estimated that almost 558 000 cases of rifampin-resistant 
TB (RR TB) occurred in 2017. Among them, 8.5% were cases of 
extensively drug-resistant (XDR) TB [1]. It is well known that 
the treatment of MDR TB is difficult due to the limitations of 
effective drugs, frequent adverse events, and prolonged treatment 
periods. With such obstacles, the global treatment success rates of 
MDR TB have been reported to be <70% [2, 3].
Fluoroquinolones (FQs) are considered the most important 
component of MDR TB treatment regimens [4]. In December 
2018, the WHO released guidelines for MDR and RR TB describing 
key changes in recommended MDR TB treatment [5], based on a 
recent large-scale meta-analysis [3] and clinical trials investigating 
new drugs and repurposed drugs [6–8]. In those guidelines, FQ 
remains to be classified as a group A drug that should be recom-
mended to all MDR TB patients. South Korea has a relatively high 
TB burden [9], and FQ resistance rates of 25%–30% have been 
reported among MDR TB patients [10]. Therefore, treatment of 
FQ-resistant MDR TB (including XDR TB) is a very important 
part of national TB control. The aim of the current study was to 
determine treatment outcomes and risk factors associated with 
treatment failure of MDR TB, focusing on FQ resistance.
METHODS
Study Population and Data Collection
The present study included patients who were diagnosed 
with MDR TB and treated at Severance Hospital, a 2500-bed 
university tertiary referral hospital in Seoul, South Korea, 
between January 2005 and December 2017. Medical records 
including demographic features and the results of laboratory, 
radiographic, and microbiological tests were retrospectively 
reviewed. Patients were treated by a TB specialist, and consec-
utive sputum cultures were performed during treatment peri-
ods according to the prescribed protocol. The research protocol 
was approved by the Institutional Review Board of Severance 
Hospital (No. 4-2018-0897). The requirement for informed con-
sent was waived due to the retrospective nature of the analysis.
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TB Definitions
MDR TB was defined as TB resistant to isoniazid and rifampin, 
and XDR TB was defined as MDR TB with additional resistance 
to both FQ and at least 1 second-line injectable drug (SLID). 
Pre-XDR TB was defined as MDR TB with resistance to an FQ 
or SLID, but not both.
Acid-Fast Bacillus Cultures and Drug Susceptibility Testing
Acid-fast bacillus cultures were examined by fluorochrome 
staining using auramine–rhodamine and culturing in 3% 
Ogawa medium and mycobacteria growth-indicator tube 
medium (MGIT; Becton Dickson, NJ, USA). MGIT has been 
used since 2008. Sputum cultures were repeated at least monthly 
until culture conversion and every 1 or 2  months thereafter. 
Drug susceptibility testing (DST) of Mycobacterium tuberculosis 
isolates was conducted at the Korean Institute of Tuberculosis 
(KIT) until December 2016, and at Seoul Clinical Laboratories 
(SCL) thereafter. DST was conducted at the KIT using the abso-
lute concentration method with Lowenstein-Jensen medium 
[11], and SCL performed DST using agar proportion methods 
with Middlebrook 7H10 medium. The drugs and correspond-
ing concentrations used are listed in Supplementary Table 1. 
Pyrazinamide susceptibility was determined via pyrazinami-
dase [12]. All patients also underwent molecular DST, and 
when there was a discrepancy between molecular DST and phe-
notypic DST, we enrolled the patient according to phenotypic 
DST results. In the analyses of drug effectiveness, some drugs 
were deemed effective if tuberculosis isolates were susceptible 
to those drugs. Drugs such as clofazimine, linezolid, carbapen-
ems, bedaquiline, and delamanid were assumed to be effective, 
as there is or was no drug susceptibility test for those drugs [3].
MDR TB Treatment and Treatment Outcomes
Although MDR TB treatments were individually determined by 
the relevant physician on a case-by-case basis, the principles of 
treatment were based on WHO recommendations [4, 13]. Only 
TB drugs used from the start of the MDR TB regimen after 
confirmation of DST and drugs used for at least 4 weeks were 
included and analyzed. According to the government policy 
for TB control, most MDR TB patients began treatment with 
hospitalization until patients were no longer considered infec-
tious. Treatment outcomes were defined based on the revised 
2013 WHO recommendations [14]. A patient was classified as 
“cured” if they completed treatment without treatment failure, 
as evident in at least 3 consecutive negative culture results at 
least 30 days apart after the intensive phase. “Treatment comple-
tion” was defined as a patient who had completed the treatment 
according to the program protocol but did not meet the defini-
tion for cured because of a lack of bacteriological results. A given 
treatment was deemed to have “failed” if a permanent change in 
treatment regimen was required due to (1) lack of conversion at 
the end of the intensive phase, (2) bacteriological reversion in 
the continuation phase after negative conversion, (3) additional 
acquired resistance to FQ or SLID, or (4) adverse drug responses. 
If patients died for any reason during the course of treatment, 
the outcome of these patients was designated “died.” “Lost to fol-
low-up” was defined as treatment interruption for ≥2 consecu-
tive months. Patients with no treatment outcome assigned were 
classified as “not evaluated.” If a cured patient or a patient who 
completed therapy resumed treatment >6 months after comple-
tion of the first treatment because of the emergence of MDR TB 
bacilli, the patient was classified as having a disease “relapse.” In 
the analysis of predictors of unfavorable outcomes, we compared 
treatment success (defined as cured or completion) with failure 
or relapse. We did not combine the outcomes of death and fail-
ure or relapse, because these cannot be considered equivalent 
[3] and deaths during the course of TB treatment in our study 
were mostly due to TB-unrelated causes. Adverse drug reactions 
included both abnormalities in medical examinations and sub-
jective symptoms reported by the patients.
Statistical Analysis
Continuous variables are presented as mean  ±  SD or median 
and interquartile range (IQR). Categorical variables are pre-
sented as number and percentage and were compared using the 
chi-square test or Fisher exact test. The Student t test and the 
Mann-Whitney test were used to compare continuous variables. 
To investigate predictors of treatment outcomes, we compared 
clinical variables in the treatment success and treatment failed 
or relapsed groups using univariate analysis. P values <.05 were 
considered statistically significant. All analyses were performed 
using SPSS software, version 23.0 (IBM, Armonk, NY, USA).
RESULTS
Baseline Patient Characteristics
Baseline characteristics of patients with FQ-S MDR TB and 
FQ-R MDR TB are shown in Table 1. Of the total 129 MDR TB 
patients, 79 (61.2%) were male, and the median age (range) was 
39.7 (17–87) years. The most common comorbidity was diabe-
tes mellitus (n = 28, 21.7%), followed by hypertension (n = 19, 
14.7%), then malignancy (n = 16, 12.4%). None of the patients 
were infected with HIV. There were no significant differences 
in age, gender, underlying comorbidities, or laboratory findings 
between the 2 groups. Notably, however, 50/90 (55.6%) FQ-S 
MDR TB patients had no history of previous TB treatment, 
whereas only 9/39 (23.1%) FQ-R MDR TB patients revealed 
no previous TB treatment history (P =  .001). Cavitary lesions 
and bilateral disease, as determined via chest radiography, were 
also more prevalent in cases of FQ-R MDR TB than in cases 
of FQ-S MDR TB (cavitary lesions 59.0% vs 38.9%, P =  .035; 
bilateral disease 66.7% vs 47.8%, P = .048). With regard to drug 
resistance patterns, 85 patients (65.9%) had FQ-S and SLID-
sensitive MDR TB, 5 (3.9%) had pre-XDR TB resistant to SLID, 
28 (21.7%) had pre-XDR TB resistant to FQ, and 11 (8.5%) had 
XDR TB resistant to both SLID and FQ.
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Treatment Modalities and FQ Resistance
Table 2 shows treatment modalities according to FQ resistance. 
Overall, FQ-R MDR TB patients tended to be treated with 
greater numbers of drugs for longer periods of time, compared 
with FQ-S MDR TB patients (median number of drugs used, 6 
vs 5; P = .043; median treatment duration, 24.0 vs 21.8 months; 
P = .027). Linezolid was used in 20/39 (51.3%) FQ-R MDR TB 
patients and 7/90 (7.8%) FQ-S MDR TB patients (P  <  .001). 
Bedaquiline and delamanid were also used more frequently in 
FQ-R patients than in FQ-S patients, but the difference was not 
statistically significant. Surgical resection was performed more 
frequently in patients with FQ-R MDR TB (11/39, 28.2%) than 
in those with FQ-S MDR TB (4/90, 4.4%; P < .001).
Adverse Drug Reactions
Table 3 shows the drug-related side effects observed in the 
treated MDR TB patients. Regardless of FQ resistance, gastro-
intestinal symptoms were the most common adverse reactions, 
occurring in 92 of the 129 patients (71.3%). Tinnitus or hear-
ing difficulty developed in 32/90 (35.6%) of the patients with 
FQ-S MDR TB and 25.6% (10/39) of the patients with FQ-R 
MDR (P  =  .270). Hematologic abnormalities occurred more 
frequently in FQ-R MDR TB patients than in FQ-R MDR TB 
patients (6/39, 15.4%, vs 5/90, 5.6%; P = .087), and peripheral 
neuropathy was more frequent in FQ-R MDR TB patients 
than in FQ-S MDR TB patients (13/39, 33.3%, vs 7/90, 7.8%; 
P  <  .001). These observations were possibly associated with 
the more frequent use of linezolid in this group [15]. Only 2 of 
the patients included in the study (1.5%) experienced QT pro-
longation. In 1 of these cases, it may have been associated with 
quinolone, and in the other it was associated with the use of 
delamanid.
Treatment Outcomes
Table 4 shows treatment outcomes in 124 patients according 
to FQ resistance. Five patients were excluded due to ongoing 
treatment status. Overall, 95/124 patients (76.6%) had success-
ful treatment outcomes, including cure (94/124, 75.8%) and 
treatment completed (1/124, 0.8%). FQ-R group showed longer 
time to sputum culture conversion (median, 1.9 vs 0.93 months; 
Table 1. Baseline Clinical Characteristics of 129 Patients With MDR TB
Total (n = 129) FQ-S MDR TB (n = 90, 69.8%) FQ-R MDR TB (n = 39, 30.2%) P
Age, y 39.7 (17–86) 38.3 (19–86) 40.0 (17–86) .955
Male gender 79 (61.2) 54 (60.0) 25 (64.1) .660
BMI, kg/m2 20.7 (13.5–41.7) 20.6 (13.5–28.7) 21.0 (16.5–41.7) .361
Current or former smoker 54 (41.9) 36 (40.0) 18 (46.2) .515
Comorbidities     
 Diabetes 28 (21.7) 19 (21.1) 9 (23.1) .804
 HTN 19 (14.7) 16 (17.8) 3 (7.7) .138
 Chronic liver diseases 9 (7) 5 (5.6) 4 (10.3) .452
 Chronic renal failure 8 (6.2) 8 (8.9) 0 .105
 Respiratory disease 7 (5.4) 6 (6.7) 1 (2.6) .674
 Malignancy 16 (12.4) 13 (14.4) 3 (7.7) .389
 Immunosuppression 2 (1.6) 2 (2.2) 0 1.0
Previous TB treatment history     
 None 59 (45.7) 50 (55.6) 9 (23.1) .001
 Firstline only 47 (36.4) 35 (38.9) 12 (30.8) .379
 Second-line 23 (17.8) 5 (5.6) 18 (46.2) <.001
Laboratory test, mean ± SD     
 Hb, g/dL 13.3 ± 2.07 13.2 ± 2.14 13.6 ± 1.89 .348
 Protein, g/dL 7.0 ± 0.65 7.0 ± 0.67 7.2 ± 0.56 .128
 Albumin, g/dL 4.1 ± 0.57 4.1 ± 0.62 4.1 ± 0.44 .637
 Cholesterol, mg/dL 161.3 ± 34.91 161.3 ± 36.71 161.3 ± 30.83 .996
Radiographic finding     
 Cavity lesions 58 (45.0) 35 (38.9) 23 (59.0) .035
 Bilateral disease 69 (53.5) 43 (47.8) 26 (66.7) .048
Positive AFB smear at treatment initiation 56 (43.4) 30 (33.3) 26 (66.7) <.001
Drug resistance pattern     
 SLID-S, FQ-S MDR 85 (65.9) 85 (94.4) 0  
 FQ-S, SLID-R, MDR (pre-XDR) 5 (3.9) 5 (5.6) 0  
 SLID-S, FQ-R, MDR (pre-XDR) 28 (21.7) 0 28 (71.8)  
 XDR 11 (8.5) 0 11 (28.2)  
Data are presented as No. (%), mean ± SD, or median (range).
Abbreviations: AFB, acid-fast bacilli; BMI, body mass index; FQ, fluoroquinolone; HTN, hypertension; MDR TB, multidrug-resistant tuberculosis; R, resistant; S, sensitive; SLID, second-line 
injectable drug; TB, tuberculosis; XDR, extensively drug-resistant.
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Table 3. Adverse Drug Reactionsa in Patients With MDR TB
Adverse Drug Reactionsa Total MDR TB (n = 129) FQ-S MDR TB (n = 90) FQ-R MDR TB (n = 39) P
Gastrointestinal trouble 92 (71.3) 66 (73.3) 26 (66.7) .442
Musculoskeletal painb 46 (35.7) 35 (38.9) 11 (28.2) .245
Ototoxicityc 42 (32.6) 32 (35.6) 10 (25.6) .270
Dermatologic abnormalities 34 (26.4) 24 (26.7) 10 (25.6) .903
Endocrine abnormalitiesd 29 (22.5) 19 (21.1) 10 (25.6) .571
Hepatotoxicity 21 (16.3) 15 (16.7) 6 (15.4) .856
Peripheral neuropathy 20 (15.5) 7 (7.8) 13 (33.3) <.001
Psychotic problems 14 (10.9) 11 (12.2) 3 (7.7) .550
General weakness 12 (9.3) 8 (8.9) 4 (10.3) .753
Hematologic abnormalitiese 11 (8.5) 5 (5.6) 6 (15.4) .087
Eye toxicity 9 (7.0) 6 (6.7) 3 (7.7) 1.0
Renal toxicity 6 (4.7) 6 (6.7) 0 (0) .178
QT prolongation 2 (1.6) 2 (2.2) 0 (0) 1.0
Othersf 6 (4.7) 6 (6.7) 0 .177
Data are presented as No. (%).
Abbreviations: FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-sensitive; MDR TB, multidrug-resistant tuberculosis.
aIncluded any drug adverse events, not only abnormality in medical test but also patients’ subjective symptoms.
bMusculoskeletal pain included myalgia and joint pain, based on patients’ subjective symptoms.
cTinnitus or hearing difficulty was based on subjective symptoms and auditory testing. Only newly developed symptoms after MDR TB treatment were included.
dEndocrine abnormalities were mainly hypothyroidism, and some hypoglycemia or hyperglycemia were also reported.
eDecrease of leukocyte, hemoglobin, or platelet count less than the lower normal limit.
fOther: fever, alopecia, anaphylactic shock.
Table 2. Treatment Modalitiesa According to Fluoroquinolone Resistance
Treatment Regimensa Total MDR TB (n = 129) FQ-S MDR TB (n = 90) FQ-R MDR TB (n = 39) P
Rifabutin 7 (5.4) 1 (1.1) 6 (15.4) .003
Ethambutol 25 (19.4) 19 (21.1) 6 (15.4) .450
Pyrazinamide 77 (59.7) 62 (68.9) 15 (38.5) .001
Fluoroquinolone     
Levofloxacin 42 (32.6) 36 (40.0) 6 (15.4) .006
Moxifloxacin 74 (57.4) 60 (66.7) 14 (35.9) .001
Ofloxacin 1 (0.8) 0 1 (2.6) .302
Injectable agents     
Streptomycin 21 (16.3) 15 (16.7) 6 (15.4) .856
Kanamycin 92 (71.3) 66 (73.3) 26 (66.7) .442
Amikacin 19 (14.7) 11 (12.2) 8 (20.5) .222
Prothionamide 104 (80.6) 76 (84.4) 28 (71.8) .095
Cycloserine 115 (89.1) 83 (92.2) 32 (82.1) .122
P-aminosalicylic acid 58 (45.0) 37 (41.1) 21 (53.8) .182
Clarithromycin 17 (13.2) 6 (6.7) 11 (28.2) .001
Amoxicillin/clavulanate 23 (17.8) 5 (5.6) 18 (46.2) <.001
High-dose INH 4 (3.1) 0 4 (10.3) .007
Clofazimine 2 (1.6) 0 2 (5.1) .090
Linezolid 27 (20.9) 7 (7.8) 20 (51.3) <.001
Bedaquiline 16 (12.4) 8 (8.9) 8 (20.5) .083
Delamanind 9 (7) 5 (5.6) 4 (10.3) .452
No. of drugs used, median (range) 5 (3–9) 5 (3–9) 6 (4–9) .043
No. of possibly effective drugs, median (range) 5 (2–7) 5 (3–7) 4 (2–7) <.001
Duration of SLID treatment, median (IQR), mo 7.8 (4.9–9.2) 7.1 (4.4–8.3) 9.9 (6.6–15.8) <.001
Duration of treatment, median (IQR), mo 22.6 (19.3–25.7) 21.8 (18.8–24.8) 24 (20.3–27.5) .027
Surgical resection 15 (11.6) 4 (4.4) 11 (28.2) <.001
Data are presented as No. (%) or median (range/interquartile range).
Abbreviations: FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-sensitive; INH, isoniazid; IQR, interquartile range; MDR TB, multidrug-resistant tuberculosis; SLID, second-line inject-
able drug.
aOnly TB drugs used from the start of the MDR TB regimen after confirmation of drug sensitivity testing and drugs used for at least 4 weeks were included and analyzed.
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P  =  .004) and lower 6-month conversion rate than the FQ-S 
group (29/38, 76.3%, vs 84/86, 97.7%; P < .001). However, the 
difference of time to sputum culture conversion between the 
2 groups changed over time periods (Supplementary Table 2). 
After active introduction of new drugs and repurposed drugs 
(period 2014–2017), the time to sputum culture conversion 
in FQ-R was shortened and showed no statistical difference 
between the FQ-S group and the FQ-R group. We did not detect 
a significant difference in the final treatment success rates 
between FQ-R and FQ-S MDR TB patients in the overall study 
periods (FQ-S MDR 65/87, 74.7%, vs FQ-R MDR 30/37, 81.1%; 
P = .443). Five patients died during the course of TB treatment. 
Causes of deaths were malignancy progression (3 patients), car-
diac problem (1 patient), and combined pneumonia (1 patient).
Predictors of Treatment Failure or Relapse
Comparisons between the 95 successfully treated patients and 
the 11 treatment failure or relapse patients are shown in Table 
5. There were no statistically significant differences in gender, 
TB treatment history, proportion of XDR TB or FQ resistance, 
or laboratory findings between the 2 groups. In univariate anal-
ysis, treatment failure/relapse was associated with age (odds 
ratio [OR], 1.056; 95% confidence interval [CI], 1.019–1.094; 
P  =  .003), lower body mass index (BMI; OR, 0.732; 95% CI, 
0.557–0.96; P =  .024), history of smoking (OR, 9.29; 95% CI, 
1.893–45.61; P = .006), and underlying malignancy (OR, 6.214; 
95% CI, 1.493–25.86; P = .019).
DISCUSSION
In the current study, the overall treatment success rate in MDR 
TB patients from 2005–2017 was 76.6%, and we did not detect 
a significant difference in treatment success rates of FQ-R and 
FQ-S patients. Factors such as older age, lower BMI, smoking, 
and underlying malignancy were associated with treatment fail-
ure or relapse.
FQ-R MDR TB including XDR TB has reportedly been asso-
ciated with greater rates of treatment failure than FQ-S MDR 
TB due to an absence of effective drugs [16–19]. In a recent 
meta-analysis, the overall pooled successful treatment rate for 
FQ-S MDR TB was 62%–73% between 2009 and 2016, whereas 
that of FQ-R MDR TB including XDR TB was 51%–57% during 
the same period [3]. Recently, however, MDR/XDR TB treat-
ment outcomes have been improved with the use of bedaquiline 
and delamanid [8, 20, 21], and repurposed drugs such as 
linezolid, clofazimine, and carbapenems also contributed to 
the improvement of MDR/XDR TB treatment outcomes [3, 7, 
15, 22]. In the current study, FQ-R MDR TB was associated 
with more severe clinical symptoms such as cavitary lesions, 
bilateral disease, and higher acid-fast bacillus smear positivity 
(Table 1). Moreover, FQ-R MDR TB patients tended to receive 
greater numbers of drugs for longer periods of time (Table 2). 
However, overall numbers of adverse drug reactions did not dif-
fer significantly in patients with FQ-S and FQ-R MDR TB, and 
the treatment success rates were comparable, which is prob-
ably related to the more frequent use of medications such as 
linezolid, clofazimine, bedaquiline, and delamanid in patients 
with FQ-R MDR TB (Table 2). This suggests that even in cases 
of FQ-R MDR TB including XDR TB, improved treatment out-
comes can be achieved if appropriate drug combinations are 
used. Several recent studies using new drugs or repurposed 
drugs also yielded results consistent with the present study, in 
which the treatment success rate of XDR TB was not inferior to 
that of MDR TB [21, 23–25].
Table 4. Treatment Outcomes in Patients With MDR TB
Total MDR TB (n = 124) a FQ-S MDR (n = 87) FQ-R MDR (n = 37) P
Treatment success 95 (76.6) 65 (74.7) 30 (81.1) .443
 Cure 94 (75.8) 64 (73.6) 30 (81.1)  
 Completion 1 (0.8) 1 (1.1) 0  
Treatment failure or relapse 11 (8.9) 8 (9.2) 3 (8.1) 1.0
 Failure 9 (7.3)b 7 (8.0) 2 (5.4)  
 Relapse 2 (1.6) 1 (1.1) 1 (2.7)  
Othersc     
 Death 5 (4.0)d 5 (5.7) 0 .321
 Lost to FU 7 (5.6) 6 (6.9) 1 (2.7) .673
 Not evaluated 6 (4.8) 3 (3.4) 3 (8.1) .362
Time to sputum culture conversion, mo 1.07 (0.05–2.37) 0.93 (0–1.93) 1.9 (0.64–5.93) .004
6-mo culture conversion, No (%) 113/124 (91.1) 84/86 (97.7) 29/38 (76.3) <.001
Data are presented as No. (%) or median (interquartile range).
Abbreviations: FQ-R, fluoroquinolone-resistant; FQ-S, fluoroquinolone-sensitive; FU, follow-up; MDR TB, multidrug-resistant tuberculosis.
aAnalysis was performed after exclusion of 5 patients due to ongoing treatment status.
bSix patients had their treatment terminated earlier due to adverse drug reactions, and 3 patients were defined as failure due to lack of culture conversion by the end of the intensive phase.
cExcluded from further analysis.
dCauses of deaths were malignancy progression (3 patients), cardiac problem (1 patient), and combined pneumonia (1 patient).
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In the present study, lower BMI was associated with treat-
ment failure/relapse. This is consistent with several previous 
studies and a meta-analysis indicating that low BMI is a risk 
factor for worse outcomes and death in MDR TB and XDR TB 
patients [24, 26–28]. Malnutrition has well-established effects 
on immune function [29], and the accompanying reduction in 
immunity may increase susceptibility to M.  tuberculosis [27]. 
Several studies have shown that smoking also increases the 
risk of developing TB and adversely affects baseline disease 
severity, bacteriological responses, treatment outcomes, and 
relapses in cases of drug-susceptible TB [30–33] and MDR TB 
[34–36]. Chronic exposure to tobacco impairs the normal clear-
ance of secretions on bronchial mucosal surfaces and reduces 
the host’s defense capacity, resulting in increased susceptibility 
to M.  tuberculosis [31]. Smoking also impairs the function of 
alveolar macrophages and reduces phagocytic ability, which 
is an important component of early host defense [37]. The 
International Union Against Tuberculosis and Lung Disease 
(Paris, France) emphasized the importance of smoking cessa-
tion in TB management, and recommended a programmatic 
approach beyond smoking cessation advice by physicians [38]. 
Despite the exclusion of deaths in the analysis of predictors of 
unfavorable outcomes, this study still showed that malignancy 
was associated with treatment failure/relapse. Previous studies 
have reported that patients with malignancy had an increased 
risk of developing TB and had poor treatment outcomes 
[39–41].
The present study suggests that improved treatment out-
comes can be achieved via effective drug combinations and 
appropriate use of new drugs for optimal treatment durations, 
even in cases of FQ-R/XDR TB, and highlights an association 
between the patient’s general condition and poor clinical out-
comes. Substantial interventions such as increased nutrition 
and smoking cessation via multidisciplinary approaches also 
need to be considered to enhance the patient’s general condition 
and further improve MDR TB treatment outcomes.
The limitations of the present study include its retrospective 
nature and relatively small sample size, which had insufficient 
statistical power to find a significant difference between FQ-R 
and FQ-S groups. Furthermore, we were unable to adjust for 
covariates based on the small sample size and few poor out-
comes observed. As the study was also conducted at a single 
university hospital, the results are not necessarily represen-
tative of the overall population of South Korea. However, the 
majority of drug-resistant TB patients are treated at university 
hospitals and TB special hospitals in South Korea. Therefore, 
despite the main study limitations, the results of the study 
will contribute to a better understanding of the current state 
of MDR TB treatment outcomes, especially in cases of FQ-R 
MDR TB in South Korea.
Table 5. Clinical Characteristics Comparison According to Treatment Outcomes and Predictors of Treatment Failure or Relapse
Variables Treatment Success (n = 95) Failure or Relapsed (n = 11) ORa (95% CI) P
Age, y 35.6 (28.8–50.1) 62.6 (47.3–73.2) 1.056 (1.019–1.094) .003
Male gender 55 (57.9) 8 (72.7) 1.939 (0.484–7.771) .519
BMI, kg/m2 21.0 (19.2–22.7) 19.9 (17.8–20.2) 0.732 (0.557–0.96) .024
Current or former smoker 31 (32.6) 9 (81.8) 9.29 (1.893–45.61) .006
Previous TB treatment Hx 53 (55.8) 5 (45.5) 0.66 (0.188–2.314) .54
DM 17 (17.9) 4 (36.4) 2.622 (0.689–9.971) .222
Chronic renal disease 4 (4.2) 1 (9.1) 2.275 (0.231–22.39) .428
Chronic liver disease 6 (6.3) 1 (9.1) 1.483 (0.162–13.6) .547
Malignancy 8 (8.4) 4 (36.4) 6.214 (1.493–25.86) .021
XDR 8 (8.4) 0 (0) 0.916 (0.862–0.973) 1
FQ-R 30 (31.6) 3 (27.3) 0.813 (0.201–3.281) 1
AFB smear positive 43 (45.3) 4 (36.4) 0.691 (0.19–2.518) .751
Cavity 45 (47.4) 3 (27.3) 0.417 (0.104–1.667) .338
Bilateral 50 (52.6) 5 (45.5) 0.75 (0.214–2.626) .652
Hemoglobin, g/dL 13.7 (12.4–14.7) 13.8 (13.0–14.4) 0.947 (0.698–1.283) .724
Protein, g/dL 7.1 (6.8–7.5) 7.2 (6.7–7.6) 1.076 (0.363–6.19) .894
Albumin, g/dL 4.2 (3.9–4.4) 4.2 (4.0–4.3) 0.626 (0.211–1.855) .398
No. of used possible effective drugs 5 (4–5) 5 (3–5) 0.971 (0.559–1.686) .917
Surgery 11 (11.6) 3 (27.3) 2.864 (0.66–12.43) .159
Linezolid 19 (20.0) 4 (36.4) 2.286 (0.606–8.62) .248
Bedaquiline 12 (12.6) 0 (0) 0.874 (0.809–0.943) .357
Delamanid 6 (6.3) 0 (0) 0.937 (0.889–0.987) 1
Data are presented as No. (%) or median (interquartile range).
Abbreviations: AFB, acid-fast bacilli; BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; FQ-R, fluoroquinolone-resistant; Hx, history; OR, odds ratio; TB, tuberculo-
sis; XDR, extensively drug-resistant.
aOdds ratio for failure or relapse vs treatment success.
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CONCLUSIONS
Overall, 76.6% of MDR TB patients had successful treatment 
outcomes in the present study, and FQ-R MDR TB and XDR 
TB were associated with comparable treatment outcomes. With 
the introduction of new and repurposed drugs, poor clinical 
outcomes were more related to the patient’s general condition, 
such as old age, low BMI, smoking, and underlying malignancy, 
rather than FQ resistance and XDR.
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